metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
multiple myeloma - 1st line (L1) multiple myeloma - 1st line (L1)
versus lenalidomide and dexamethasone
	pembrolizumab plus lenalidomide and dexamethasone
	KEYNOTE-185, 2019 Lancet Haematol 2019; 6:e448-e458 Int J Hematol 2020 Nov;112(5):640-649. NCT02579863	RCT	multiple myeloma - 1st line (L1)	pembrolizumab plus lenalidomide and dexamethasone	lenalidomide and dexamethasone	Transplantation-ineligible patients with newly diagnosed active multiple myeloma, who were treatment naive were enrolled,	151 / 150	some concern	safety concern	safety concern with 22 % increase in progression or deaths (PFS) (PE) (not statistically significant)
multiple myeloma - 2nd line (L2) multiple myeloma - 2nd line (L2)
versus pomalidomide and dexamethasone
	pembrolizumab plus pomalidomide and dexamethasone
	KEYNOTE-183, 2019 Lancet Haematol 2019; 6:e459-e469 Int J Hematol 2021 Apr 15. NCT02576977	RCT	multiple myeloma - 2nd line (L2)	pembrolizumab plus pomalidomide and dexamethasone	pomalidomide and dexamethasone	patients with relapsed or refractory multiple myeloma and at least two previous lines of anti-myeloma therapy,	125 / 124	some concern	safety concern	safety concern with 61 % increase in deaths (OS) (PE) (not statistically significant) safety concern with statistically significant 53 % increase in progression or deaths (PFS) (PE)